Correction to: A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent

1 Correction to: American Journal of Cardiovascular Drugs https://doi.org/10.1007/s40256-021-00499-1

In this article Fig. 2 was inadvertently published as Fig. 2a and 2b

The Fig. 2 should have appeared as shown below.

Fig. 2

Mechanism of action of pelacarsen [20, 31]. Schematic overview of pelacarsen’s mechanism of action. Pelacarsen targets LPA gene mRNA and prevents apo(a) production leading to decrease Lp(a) particle assembly.

The original article has been corrected